Colorectal Cancer Highlights from ASCO 2020

Benjamin A. Weinberg, MD


June 24, 2020

Dr Benjamin Weinberg from the Lombardi Comprehensive Cancer in Washington, DC, discusses key studies from the ASCO 2020 virtual meeting for patients with metastatic colorectal cancer (mCRC).

The KEYNOTE-177 trial, presented at the plenary session, establishes a new standard of care for MSI-H mCRC patients. In this trial, PFS was improved by 8.3 months when pembrolizumab versus chemotherapy was used in the front-line setting.

The DESTINY-CRC01 trial looked at trastuzumab deruxtecan, an antibody–drug conjugate, in refractory HER2-expressing mCRC patients. The trial demonstrated an impressive response rate, which will require further studies.

The RAPIDO trial showed that a short course of radiation is similar to the traditional 5.5 weeks of chemoradiation in patients with high-risk, locally advanced rectal cancer. The trial data suggest radiation alone may be superior to chemoradiation in several measures, including complete pathological response rate. Dr Weinberg comments that these results mark a new standard of care.

Finally, Dr Weinburg discusses two additional presentations that answer critical questions regarding duration of adjuvant chemotherapy and whether chemotherapy after resection of liver metastases provides survival benefit.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.